Corporate Banner
Satellite Banner
Genotyping & Gene Expression
Scientific Community
Become a Member | Sign in
Home>News>This Article

Agilent Updates Human Exon Target Enrichment Tool, Featuring Expressed Genome Content and Optimized Uniformity

Published: Wednesday, August 25, 2010
Last Updated: Wednesday, August 25, 2010
Bookmark and Share
The Latest SureSelect product to emerge from close collaboration with The Broad Institute.

Agilent Technologies Inc. has introduced the SureSelect Human All Exon v2 Target Enrichment kit, which was developed in close collaboration with the Broad Institute of MIT and Harvard.

The kit, the 15th SureSelect product in Agilent’s portfolio, is a single tube assay that allows researchers to streamline experiments by sequencing the expressed genome while discarding regions not of interest.

The company informs that its SureSelect platform is well-proven for enabling genetic discovery, evidenced by recent key discoveries into Mendelian diseases and heritable cancer. This year alone, the SureSelect Target Enrichment System has been cited in eight papers covering research into a wide range of heritable disorders.

Agilent offers an industry-leading three All Exon designs, two developed with the Broad Institute and one developed with the Wellcome Trust Sanger Institute and Gencode. The original Agilent Human All Exon Target Enrichment kit was introduced in September 2009. The new 38 megabase (Mb) kit design adds content recently determined to be in the expressed genome. This content also is found in Agilent’s second product targeting the human exome, the SureSelect Human All Exon 50 Mb kit, developed in partnership with the Wellcome Trust Sanger Institute and Gencode.

“We are happy with the most recent outcome of our long-standing collaboration with Agilent,” said Stacey Gabriel, Ph.D., co-director of the Genome Sequencing Center at the Broad Institute. “At Broad, we are continually developing our protocols to improve performance and enable the most efficient discoveries in human genetics. This new product from Agilent is just one of several anticipated improvements we will make available with Agilent to geneticists.”

“The Broad Institute has been utilizing this updated version of the Human All Exon kit for several months, and it works very well in our production pipeline,” added Sheila Fisher, assistant director of Technology Development for the Genome Sequencing Center at the Broad Institute. “We have used this kit to successfully target and sequence the exomes of more than 5,100 human samples from a variety of cancer and heritable disease studies.”

“The Broad Institute worked with us to define the first version of the SureSelect Human All Exon kit,” said Emily M. LeProust, Ph.D., Agilent director of Genomics Application Development, “and has continued this relationship to further define and improve the performance of this already powerful capture technology. We believe that it will continue to be a highly useful research tool for discovery of mutations linked to heritable disease and cancer.”

The SureSelect Human All Exon v2 kit design covers:

• 99.01 percent of human exons defined by the NCBI Consensus CDS Database from September 2009;

• 93.29 percent of RefSeq genes;

• 95.07 percent of RefSeq transcripts from June 2010; and

• 90 percent of miRNA in miRBase v14.

The kit targets just over 38 Mb of the human genome in a single tube reaction. In addition to the new content, teams at the Broad Institute and Agilent have carefully re-balanced the mixture of probes to maximize capture efficiency and uniformity across the exome.

Agilent’s SureSelect Target Enrichment System offers the broadest range of target enrichment products and the most highly optimized protocols for a diverse set of sequencing methods and platforms. There are now 15 products in the SureSelect portfolio, with many more in development.

SureSelect products are available for enrichment of target sizes ranging from smaller than 200 Kb to more than 50 Mb in a single tube. Protocols now support Illumina end sequencing, paired-end sequencing and indexing protocols in addition to fragment library format, paired-end sequencing and barcoding on the SOLiD System.

Users of Agilent’s eArray xD desktop design tool can improve the efficiency of their research by easily designing custom products to target any genome of interest, all in a single tube. Agilent also offers the eArray online design tool, enabling users to customize pre-defined SureSelect kits such as the SureSelect Human All Exon series of products.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Agilent Supports Inaugural Singapore-South Korea Symposium on Glycomics
Event follows collaboration to develop tools for analysis of biologics, vaccines.
Saturday, February 15, 2014
Agilent, Cell Line Genetics Collaborate
Companies to collaborate on high-throughput cell-line characterization services for regenerative medicine, cancer researchers.
Thursday, February 13, 2014
Agilent Joins Forces with Baylor College of Medicine
Collaboration will see Agilent and Baylor provide customized CGH microarrays for cancer, prenatal and postnatal research.
Thursday, November 14, 2013
Agilent and Seoul National University Hospital Collaborate
The strategic collaboration will focus on the development and verification of various biomarkers for the development of drugs, including narcotics, immune-suppressants and biomarkers.
Friday, October 18, 2013
Agilent Technologies to Separate into Two Public Companies
Life sciences, diagnostics and applied markets (LDA) that will retain the Agilent name, and the other company will be comprised of Agilent's electronic measurement (EM) products.
Monday, September 23, 2013
Agilent Technologies and SomaLogic Enter Agreement
The agreement will expand access to SomaLogic's unbiased protein biomarker discovery platform.
Tuesday, August 13, 2013
Agilent Technologies Announces Winner of Fifth Annual Early Career Professor Award
Assistant Professor at Northwestern Recognized for Cancer Diagnostics Research.
Friday, May 10, 2013
Agilent Technologies and Chungnam National University Announce Glycomics Research Initiatives
The collaboration hopes to develop biomarkers and new therapeutic antibodies to combat diseases such as cancer.
Tuesday, April 02, 2013
Agilent and Applied Proteomics Will Collaborate
Collaboration to maximize capabilities of highly multiplexed protein assays.
Friday, March 08, 2013
Agilent Technologies Collaborates with Gachon University
World-leading research laboratory at Gachon will have access to the latest technologies from Agilent and a beta test site for new solutions.
Monday, July 23, 2012
Agilent Technologies and Chungnam National University Collaborate to Further Glycomics Research
The university aims to identify and develop biomarkers for diseases.
Friday, August 26, 2011
Agilent Technologies Enters Second Phase of Collaboration to Map Human Proteome
Agilent’s collaboration with ISB and ETH Zurich for the mapping of the complete human proteome by mass spectrometry is enters its second phase.
Thursday, September 23, 2010
Agilent and Los Alamos Develop First High-Throughput System to be Deployed at UCLA’s Global Bio Lab
Researchers are developing new tools for characterizing biological pathogens that could give rise to potentially deadly pandemics.
Thursday, June 11, 2009
Phytronix and Agilent to Co-Market Phytronix LDTD Ion Source with Agilent Mass Spectrometers
The non-exclusive co-marketing agreement aims to promote the Phytronix Laser Diode Thermal Desorption Ion Source with Agilent mass spectrometers.
Wednesday, June 10, 2009
Agilent Technologies, University of Michigan Partner on Research to Attack Prostate Cancer Using Systems Biology
Agilent Technologies announced its support of prostate cancer research by the University of Michigan’s Centre for Translational Pathology (MCTP) through a grant of instruments and funding.
Monday, March 23, 2009
Scientific News
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Mathematical Model Forecasts the Path of Breast Cancer
Chances of survival depend on which organs breast cancer tumors colonize first.
Ancient Viral Molecules Essential for Human Development
Genetic material from ancient viral infections is critical to human development, according to researchers at the Stanford University School of Medicine.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Personalized Drug Screening for Multiple Myeloma Patients
A personalized method for testing the effectiveness of drugs that treat multiple myeloma may predict quickly and more accurately the best treatments for individual patients with the bone marrow cancer.
Metabolic Profiles Distinguish Early Stage Ovarian Cancer with Unprecedented Accuracy
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
New Way to Force Stem Cells to Become Bone Cells
Potential therapies based on this discovery could help people heal bone injuries or set hardware, such as replacement knees and hips.
Promise of Newborn Stem Cells to Revolutionize Clinical Practice
In this article Shweta Sharma, PhD, discusses the potential of an Umbilical Cord Blood bank as an untapped source of samples for research and clinical trials.
New Anti-Malarial Drug Screening Model
University of South Florida researchers demonstrate novel chemogenomic profiling to identify drug targets for the most lethal strain of malaria.
Coronavirus Breakthrough
Protein mutation affects spread and virulence of respiratory virus.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos